Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers.

about

Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers.

Item

http://www.wikidata.org/entity/Q38625769

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers.

@en

type

Item

label

Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers.

@en

prefLabel

Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers.

@en

P1476

Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers.

@en

P2093

C Choi

http://www.w3.org/2001/XMLSchema#string

C O Kim

http://www.w3.org/2001/XMLSchema#string

E S Oh

http://www.w3.org/2001/XMLSchema#string

K H Kim

http://www.w3.org/2001/XMLSchema#string

M S Park

http://www.w3.org/2001/XMLSchema#string

S J Kim

http://www.w3.org/2001/XMLSchema#string

Y N Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors.

A family of drug transporters: the multidrug resistance-associated proteins.

Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions.

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

Standards of medical care in diabetes-2015 abridged for primary care providers.

Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man

Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes

The human hepatic cytochromes P450 involved in drug metabolism.

Oral antidiabetic agents in type 2 diabetes.

P31

scholarly article

P356

10.1111/JCPT.12604

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28806472

http://www.w3.org/2001/XMLSchema#string